T-Cell Therapy (ECT204) in Adults With Advanced HCC

Study Number

3610823

Phase

Age Group

Adult

Principal Investigator

Purpose

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.

Check your eligibility for this trial

Check now

Full Title

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults with Advanced Hepatocellular Carcinoma (HCC).

ClinicalTrials.Gov ID

NCT04864054

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.